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Abstract Objective: This study aimed to determine whether perioperative 
antiviral treatment is facilitate for patients with hepatitis B virus (HBV)-related 
hepatocellular carcinoma (HCC) and Child-Pugh grade A cirrhosis in 
perioperative recovery of liver function and HBV activation. Methods: The 
study included 115 patients with HBV-related HCC and Child-Pugh grade A 
cirrhosis who underwent resection. Patients were prospectively assigned to a 
preoperative antiviral treatment group (n = 51) or postoperative antiviral 
treatment group (n = 52); twelve patients who had not received antiviral 
treatment before and after surgery were designated a non-treatment group (n = 
12). HBV reactivation during a month after the operation was defined as a 
HBV DNA value tenfold over preoperative values. Postoperative liver 
dysfunction was defined as prothrombin activity <50% and serum bilirubin 
>50 mmol/L on postoperative day 5. Results: Postoperatively, liver 
dysfunction was present in 1 of 51 (1.96%) patients who received preoperative 
antiviral therapy, 1 of 52 (1.92%) who received postoperative therapy, and 3 of 
12 (25%) who received no antiviral therapy. HBV reactivation postoperatively 
occurred at similar rates. Conclusions: Preoperative and postoperative antiviral 
treatment of patients with Child-Pugh grade A cirrhosis and high levels of 
HBV DNA undergoing hepatic resection for HCC are both facilitate in 
preventing perioperative liver dysfunction and reactivation of HBV. Thus, in 
this population with high levels of HBV DNA, perioperative antiviral treatment 
is important. 
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1. Introduction 
Hepatitis B virus (HBV) can be activated after hepatectomy.[1-10] HBV reactivation influences postoperative recovery 
of liver function, the recurrence of liver cancer, and long-term survival after hepatectomy. [1-10]Perioperative antiviral 
treatment can reduce HBV reactivation, postoperative liver dysfunction, and recurrence of liver cancer, thereby improving 
long-term survival after resection for HBV-related hepatocellular carcinoma (HCC).[11-15] However, most of the studies 
of patients undergoing surgical treatment  for HBV-related  HCC have assessed antiviral therapy given after resection; 
few have assessed  therapy given before resection. [16] And preoperative  antiviral  therapy  is recommended  for  HBV  
carriers  who  will receive  partial  hepatectomy. [17] This study compared the relative perioperative effectiveness of 
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preoperative and postoperative antiviral treatment of patients with Child-Pugh grade A cirrhosis undergoing hepatic 
resection of HBV-related HCC; some patients who declined antiviral therapy also were evaluated. 
2. Patients and Methods 
2.1. Study design 
This study included 115 patients with HBV-related HCC and Child-Pugh grade A cirrhosis who underwent liver resection 
at the Affiliated Hospital of Guilin Medical University, Guangxi, China, between January 2014 and July 2016. Patients 
who received perioperative antiviral treatment were prospectively assigned alternately to one of two groups according to 
the sequence of admission to the hospital: preoperative antiviral treatment group (n = 51) and postoperative antiviral 
treatment group (n = 52). In the same period, 12 patients did not receive perioperative antiviral treatment and were 
designated the non-antiviral treatment group (n = 12). All patients’ preoperative HBV DNA values were higher than 2000 
IU/ml. Patients in the preoperative treatment group received orally administrated Entecavir (Dawnrays Pharmaceutical Co., 
LTD, Jiangsu, China) 0.5 mg once a day during the first 3 days before operation and until the day of operation; after 
operation, the drug was given via gastric tube until the tube was removed (usually on postoperative day 3). Patients in the 
postoperative treatment group began receiving Entecavir (0.5 mg/d) orally after the gastric tube was removed. The study 
mainly evaluated recovery of liver function and rate of HBV reactivation during 1 week and 1 month after surgery, 
respectively. 
2.2. Patients 
A total of 115 patients with HBV-related HCC who underwent liver resection were enrolled in the study, which was 
approved by The Clinical Research Ethics Committee of the Affiliated Hospital of Guilin Medical University. All assigned 
patients were given conventional perioperative prophylaxis antibiotic drugs, gastric-acid inhibitor drugs, and nutritional 
support. Resected liver tissues were examined histologically.  
The criteria for inclusion in the study were these: 1) the primary liver cancer was confirmed by preoperative clinical 
diagnosis; 2) HBV surface antigen was positive; 3) the patient had not received antiviral treatment before admission into 
this hospital; 4) the patient’s condition was satisfactory for major surgery; 5) the preoperative liver function was Child-
Pugh grade A. The exclusion criteria were these: 1) metastatic or recurrent liver cancer confirmed by postoperative 
pathologic examination; 2) concurrent hepatitis C virus or HIV; 3) serious cardiac, pulmonary or renal disease; 4) patient 
had received transarterial chemoembolization or other antitumor therapies before operation; 5) preoperative aspartate 
aminotransferase and/or alanine aminotransferase >100 U/L; and 6) pregnant or lactating women. 
2.3. Clinical diagnosis and definitions 
The cut-off of HBV DNA value for grouping was in accordance with Asian Pacific guidelines.[18] HBV reactivation 
during a month after the operation was defined as postoperative HBV DNA level increased tenfold over preoperative values. 
The diagnosis of HCC was confirmed by histopathological examination. Postoperative liver dysfunction was defined as 
prothrombin activity <50% and serum bilirubin >50 mmol/L on postoperative day 5.[19] 
2.4. Surgical methods 
The operations were conducted by surgeons skilled in liver resection. The selection of the surgical method was based on 
the results of operative exploration, preoperative examination, relevant indicators (preoperative indocyanine green retention 
rate at 15 minutes and Child-Pugh classification), and the size and location of the tumor. All patients were given intravenous 
anesthesia. The methods of liver resection (n = 115) were these: nonanatomic liver resection or local tumor resection (n = 
46), left hemihepatectomy (n = 22), right hemihepatectomy (n = 14), caudate lobe resection (n = 11), mesohepatectomy (n 
= 10), and left lateral liver resection (n = 14). The number of minor and major hepatectomy were 29 and 22 in preoperative 
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antiviral treatment group, 33 and 19 in postoperative antiviral treatment group, and 7 and 5 in non-treatment group, 
respectively. 
2.5. Biochemical tests 
Blood tests on the patients were performed after fasting overnight on the second morning after hospital admission. 
Biochemical test results were reviewed on the first, third, fifth, seventh, tenth, and fifteenth day after operation. 
Subsequently, blood tests were conducted once every month. Blood tests included routine blood, liver function, blood 
coagulation function, HBV DNA, and five indices of hepatitis b infection (hepatitis B surface antigen; antibody to hepatitis 
B surface antigen; hepatitis B e antigen; antibody to hepatitis B e antigen; and antibody to hepatitis B core antigen). Serum 
HBV DNA concentration was determined with polymerase chain reaction. 
2.6. Statistical analysis 
Normally distributed variables were presented as mean ± standard deviation and compared by the t-test. Classification 
variables were compared by use of chi-squared tests. All analyses were performed with the SPSS 19.0 software for windows 
(SPSS Inc., IL, USA). P < 0.05 was considered statistically significant. 
3. Results 

















Age (years) 50.85±10.63 49.36±11.46 44.92±13.88 0.616   0.539 1.585 0.119 -1.129 0.264 
Sex 
(Female/Male) 
8/43 6/46 4/8   0.539  0.161  0.061 
Preoperative HBV 
DNA (log) 
4.55±1.08 4.51±1.16 4.97±1.09 -0.139  0.890 1.23 0.224 1.23 0.224 
Diameter of tumor 
(cm) 
6.32±4.083 6.65±4.45 6.10±3.21 -0.314  0.754 -1.57 0.876 -.359 0.721 
INR  1.02±0.07 1.03±0.09 1.04±0.12 -0.926  0.357 -0.314 0.628 0.175 0.862 
Total bilirubin 
(umol/L) 
13.52±4.68 13.64±5.24 11.91±5.58 -0.111  0.912 1.00 0.321 -0.993 0.325 
Albumin (g/L) 38.57±3.56 36.92±4.73 37.60±4.77 1.845  0.069 -0.766 0.447 0.455 0.651 
AST (U/L) 39.78±15.32 43.19±21.87 41.09±12.96 -0.822  0.413 0.217 0.787 -0.315 0.754 




29//22 33/19 7/5   0.496  0.927  0.743 
Liver dysfunction 3 3 3   0.980  0.042  0.039 
HBV reactivation  1 1 3   0.989  0.031  0.014 
AST: aspartate aminotransferase;  ALT: alanine aminotransferase; HBV: hepatitis B virus; INR: international normalized ratio;  Pre-group refers to 
patient who received antiviral treatment before operation; Post-group refers to patients who received antiviral treatment immediately after operation; 
Non-group refers to patients who did not receive antiviral treatment; t1 and P1 were the comparison between groups Pre-group and Post-group, t2 and P2 
between groups Pre-group and Non-group, and t3 and P3 between groups Post- group and Non-group. 
The clinical indexes of the three groups of patients are presented in Table 1. No differences were found in age, sex and 
preoperative values of HBV DNA concentrations, tumor diameter, international normalized ratio, total serum bilirubin, 
aspartate aminotransferasealanine aminotransferase and types of hepatectomy among the groups. Postoperatively, 
significant differences between the groups were recorded: Liver dysfunction was present in 1 of 51 (1.96%) patients who 
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received preoperative antiviral therapy and 1 of 52(1.92%) who received postoperative therapy. In contrast, 3 of 12 patients 
(25%) who received no antiviral therapy had liver dysfunction. HBV reactivation postoperatively also occurred 
significantly less frequently in patients who received preoperative antiviral therapy (1/51; 1.96%) or postoperative therapy 
(1/52; 1.92%) than in those who received no antiviral therapy (3/12; 25%).  
4. Discussion 
4.1. Perioperative antiviral treatment 
The present study found that patients who did not receive antiviral treatment had a much higher rate of postoperative 
HBV reactivation and a lower rate of postoperative recovery of liver function than did patients who received either 
preoperative or postoperative antiviral treatment. In several studies, [1,5,20-22] the rate of postoperative HBV reactivation 
was 14%–33% in patients who did not receive perioperative antiviral treatment. Related studies [1,20,22] have found the 
rate of postoperative HBV reactivation to be 1.4%–2.9% in patients with perioperative antiviral treatment. Both of these 
results are similar to the results in our study. However, none of the reported studies [9,12,14,20-22] directly compared the 
incidence of HBV reactivation or recovery of liver function in patients who received preoperative antiviral treatment with 
the incidence in those who received postoperative treatment; this comparison is a unique and important feature of our study. 
HBV, if activated, significantly impedes the recovery of liver function, increases the rate of postoperative tumor 
recurrence and reduces the survival rate. [21-24] Perioperative antiviral treatment can reduce postoperative liver damage 
and the recurrence of postoperative tumor, and can promote the recovery of liver function and improve postoperative 
survival. [11-13,23,24] Antiviral treatment can significantly decrease the reactivation of HBV in patients with HBV-related 
HCC undergoing liver resection. [1,4-10,15,21] Some authors [1,5,21] have reported a high rate of HBV reactivation and a 
high chance of liver failure in patients who had low preoperative HBV DNA values and did not receive perioperative 
antiviral treatment after liver resection. The preoperative positive serum HBV-DNA may have activated HBV after the liver 
resection, and preoperative undetectable HBV DNA did not seem to assure nonreplicating HBV after surgery;[21] 
perioperative antiviral treatment was the only factor that prevented the HBV reactivation[21]. 
4.2. Preoperative antiviral treatment 
In this study, no significant difference was found in the postoperative recovery of liver function and the rate of 
postoperative HBV reactivation between preoperative and postoperative antiviral treatment. Zhang, et al[4] reported that 
72 patients with HBV DNA >104 IU/ml received antiviral treatment with Entecavir tablets before hepatectomy; surgery 
was delayed until the HBV- DNA was less than 104 IU/ml, and patients continued to use the antiviral drugs after surgery. 
Forty patients with HBV DNA >104 IU/ml in the control group did not receive antiviral treatment before or after surgery. 
An absence of hepatitis B recrudescence and faster recovery of postoperative liver function indices were observed in the 
antiviral treatment group. Similar to our experience, preoperative antiviral treatment was similar to postoperative antiviral 
treatment for patients with preoperative high HBV DNA level and Child-Pugh grade A[12]. Preoperative antiviral treatment 
is beneficial to the patient, and it is necessary for these patients to start preoperative antiviral treatment before surgery. But 
a long time is required to control the virus, and the preoperative preparation time for patients diagnosed with HBV-related 
HCC for the first time is limited, usually 3–7 days. It is unclear whether it is necessary for these patients HBV DNA must 
be reduced to a certain level before surgery. Thus, This doubt needs further research. 
5. Conclusions 
Preoperative and postoperative antiviral treatment of patients with Child-Pugh grade A cirrhosis and high levels of HBV 
DNA undergoing hepatic resection for hepatocellular carcinoma resulted in similarly low rates (about 2%) of postoperative 
liver dysfunction and reactivation of HBV. In contrast, patients who did not receive perioperative antiviral treatment had 
higher rates (about 25%) of postoperative liver dysfunction and reactivation of HBV. Thus, in patients with high levels of 
HBV DNA, perioperative antiviral treatment is important. 
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6. Limitations of This Research 
The study included a relatively small number of cases, from a single research center. Long-term survival and tumor 
recurrence were not evaluated. The study also did not have a completely randomized design. Finally, the study’s results 
need to be validated in multicenter, prospective, randomized studies with larger numbers of patients.  
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